NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

December 13, 2022

Study Completion Date

January 23, 2023

Conditions

Atrial Fibrillation

Interventions

DRUG

AP30663

Administer by intravenous infusion.

DRUG

Placebo

Placebo matched to AP30663.

Trial Locations (15)

Acesion Pharma Investigational Site 110, Aalborg

Acesion Pharma Investigational Site 106, Copenhagen

Acesion Pharma Investigational Site 108, Hellerup

Acesion Pharma Investigational Site 113, Hillerød

Acesion Pharma Investigational Site 105, Roskilde

Acesion Pharma Investigational Site 202, Budapest

Acesion Pharma Investigational Site 203, Budapest

Acesion Pharma Investigational Site 207, Budapest

Acesion Pharma Investigational Site 212, Budapest

Acesion Pharma Investigational Site 213, Budapest

Acesion Pharma Investigational Site 214, Budapest

Acesion Pharma Investigational Site 211, Pécs

Acesion Pharma Investigational Site 201, Szekszárd

Acesion Pharma Investigational Site 210, Szentes

Acesion Pharma Investigational Site 204, Zalaegerszeg